Portal de Periódicos da CAPES

The Children's Oncology Group's 2013 five year blueprint for research

2012; Wiley; Volume: 60; Issue: 6 Linguagem: Inglês

10.1002/pbc.24399

1545-5017

Peter C. Adamson,

Acute Lymphoblastic Leukemia research

Pediatric Blood & CancerVolume 60, Issue 6 p. 955-956 Editorial The Children's Oncology Group's 2013 five year blueprint for research Peter C. Adamson MD, Corresponding Author Peter C. Adamson MD [email protected] The Children's Hospital of Philadelphia, Philadelphia, PennsylvaniaChair, Children's Oncology Group, The Children's Hospital of Philadelphia, 3501 Civic Center Blvd., CTRB 10060, Philadelphia, PA 19104.===Search for more papers by this author Peter C. Adamson MD, Corresponding Author Peter C. Adamson MD [email protected] The Children's Hospital of Philadelphia, Philadelphia, PennsylvaniaChair, Children's Oncology Group, The Children's Hospital of Philadelphia, 3501 Civic Center Blvd., CTRB 10060, Philadelphia, PA 19104.===Search for more papers by this author First published: 19 December 2012 https://doi.org/10.1002/pbc.24399Citations: 21Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1 Farber S, Diamond LK, Mercer RD, et al. Temporary remissions in acute leukemia in children produced by folic acid antagonist 4-aminopteroylglutamic acid (aminopterin). N Engl J Med 1948; 28: 787–793. 2 Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225–249. 3 Adamson PC, Blaney SM. New approaches to drug development in pediatric oncology. Cancer J 2005; 11: 324–330. 4 Bhatia S, Meadows AT. Long-term follow-up of childhood cancer survivors: Future directions for clinical care and research. Pediatr Blood Cancer 2006; 46: 143–148. 5 Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355: 1572–1582. 6 Norris RE, Adamson PC. Challenges and opportunities in childhood cancer drug development. Nat Rev Cancer 2012; 12: 776–782. DOI: 10.1038/nrc3370 Epub 2012 Oct 11. 7 Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: Challenges for the twenty-first century. J Clin Oncol 2010; 28: 2625–2634. 8 Mardis ER. A decade's perspective on DNA sequencing technology. Nature 2011; 470: 198–203. 9 O'Leary M, Krailo M, Anderson JR, et al. Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group. Semin Oncol 2008; 35: 484–493. 10 Committee on Cancer Clinical Trials and the NCI Cooperative Group Program; Institute of Medicine. 2010; A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. National Academies Press http://www.nap.edu/catalog.php?record_id=12879%3E 11 Dilts D. US cancer trials may go the way of the Oldsmobile. Nat Med 2010; 16: 632. 12 Dilts DM, Cheng SK, Crites JS, et al. Phase III clinical trial development: a process of chutes and ladders. Clin Cancer Res 2010; 16: 5381–5389. Citing Literature Volume60, Issue6June 2013Pages 955-956 ReferencesRelatedInformation